LANXESS disinfectant kills Coronavirus SARS-CoV-2 in just 60 seconds


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ disinfectant-kills-coronavirus-sars-cov2-just-60-seconds
Lanxess claims corona free surfaces in 60 seconds

Rely+On Virkon broad spectrum disinfectant, produced by specialty Chemicals Company LANXESS, demonstrates extremely rapid efficacy against the SARS-CoV-2 virus.

This is the finding of a recent study LANXESS commissioned through independent analysis laboratory Microbac Laboratories, Inc. in accordance with the U.S. Environmental Protection Agency (EPA) compliant test methods, for products intended for virucidal hard surface disinfection.

Rely+On Virkon achieved rapid and complete inactivation of the SARS-CoV-2 virus at a dilution ratio of 1:100 in just 60 seconds, and at an economical 1:600 in-use dilution with a 10 minute contact time.

Corresponding efficacy data has to be provided for disinfectants that claim to combat SARS-CoV-2. Microbac is one of the few testing laboratories worldwide that U.S. health authority CDC (Center for Disease Control) has certified to undertake such tests.“Neither a vaccine nor generally approved medications are currently available to us in the fight against the global coronavirus pandemic.So alongside social distancing and hand-washing, disinfection remains a highly important means to help prevent the spread of this life-threatening respiratory illness,” says Anneliese Bischof, Business Director Disinfection at LANXESS. “Right now, good hygiene cleaning and disinfection practices are more important than ever. The fact that Rely+On Virkon inactivates SARS-CoV-2 so quickly will help reassure people that the disinfectant product they are using is both fast and effective in practical use,” underlines Bischof.

Rely+On Virkon is a powder disinfectant concentrate diluted in water for application as a spray on hard surfaces and equipment (non-medical). It can therefore help to reduce the risk of cross-contamination from surfaces, door handles, tables or chairs during disinfection measures at public transport terminals, airports, hospitals, clinics, shopping malls, etc.

The LANXESS Material Protection Products business unit produces a wide range of scientifically based disinfection technologies under the Rely+On and Virkon brand.

LANXESS is a leading specialty chemicals company with sales of EUR 6.8 billion in 2019. The company currently has about 14,300 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

Tags : #Sars-Cov-2 #Lanxess #Disinfection #Microbac #CDC #RelyOn #Virkon

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Tier-2 and Tier-3 Cities: India's Next Big Healthcare Growth StorySeptember 18, 2026
Why Regional Hospital Chains Are Becoming More Important in IndiaSeptember 18, 2026
The Future of Indian MedTech Exports: Can India Compete With Global Leaders?September 17, 2026
Robotic-Assisted Procedures Beyond Surgery: Where Is Automation Going Next in Healthcare?September 17, 2026
58 Students from SRM Medical College Selected for Union Government Research Programmes and Grants September 16, 2026
Handpickd Questions the Role of Science in Food with ‘Science-Less’ Newspaper CampaignSeptember 16, 2026
As Women’s Cancer Burden Rises, Integrated Care Emerges as The Next Frontier in Cancer TreatmentSeptember 16, 2026
Odia Superstar Babushaan Mohanty Inaugurates Manoj Das Library at Utkal Gaurav International SchoolSeptember 16, 2026
Yashoda Hospitals, Somajiguda Successfully Treats 10-Month-Old with Complex Heart Condition Through Staged ApproachSeptember 16, 2026
Tracky launches 16D, India's first 16-day continuous glucose monitoring system (CGM)September 16, 2026
Why Local Medical Device Manufacturing Matters for Indian HealthcareSeptember 16, 2026
Next-Generation Surgical Robots Entering the Indian Market: What It Means for Patients and ProvidersSeptember 16, 2026
ShardaCare - Healthcity Marks World Sepsis Day with Training for Over 50 NursesSeptember 15, 2026
From Empowerment to Ownership: Upasana Kamineni Konidela Calls for a BRICS Women’s Economic CorridorSeptember 15, 2026
WORLD HEART DAY 2026: Don't Miss a Beat: The Heart Attacks That Never Had to HappenSeptember 15, 2026
BL Agro Announces Investment of ₹1,500 Crore In Its Biotech-Arm Leads Genetics To Build An Integrated Dairy and Genetics EcosystemSeptember 15, 2026
Can You Have PMOS With Regular Periods? What Women Often Get WrongSeptember 15, 2026
Hospital Data Breaches in India: What Every Patient Needs to Know Right NowSeptember 15, 2026
Cybersecurity of ICUs: Protecting Connected Critical-Care Systems in Indian HospitalsSeptember 15, 2026
Fortis Hospital, Shalimar Bagh Becomes Delhi NCR’s First Multi-speciality Hospital to Launch Rezūm™ Water Vapor Therapy for Enlarged ProstateSeptember 14, 2026